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ABSTRACT.
Invasive fungal infections especially in the immunocompromised patient have become a target for empiric 
and prompt preemptive therapy due to the associated high mortality and hospital costs. It is for these 
reasons that newer laboratory tests are being formulated to drive early therapeutic interventions so that 
mortality associated with invasive fungal infections can be minimized.
2 ( )
INTRODUCTION.
Candida species are the most common cause of 
fungal infections worldwide. They are implicated 
in a wide variety of infections from simple 
superficial infections to systemic infections that 
can involve virtually any organ. Blood stream 
infections by Candida are increasingly common 
1,2and often are associated with high mortality rates.  
Candida spp. is currently the 4th most frequently 
isolated pathogen from the blood stream in North 
5,6
American hospitals .
Various spp of Candida exist they include C. 
glabrata, C. krusei, C. tropicalis, C.parapsilosis, 
3,4
C. dublinensis, C.guillermondi  .
The reasons for the increase in fungal infections are 
multifactorial: better clinical evaluation and 
diagnosis, greater survival of patients with 
malignancies, chronic diseases, increasing number 
of transplants, complex surgical procedures, 
catheters, implants and use of wide spectrum 
7
antibiotics.  Mucosal colonization, neutropenia, 
previous surgical procedures (particularly 
complicated abdominal surgery), total parenteral 
nutrition and concomitant bacteremia are also 
significant risk factors for invasive Candida 
10, 11infection. 
Candidaemia is not only associated with mortality 
of about 30% to 40% but also extends the duration 
of hospital stay & also increase the cost for medical 
care. 
Its growing importance is expanding to include 
patients without neutropenia as management is 
 
becoming more difficult because of the difficulty in 
making a diagnosis in this group of patients. It may 
be too late to start appropriate treatment once the 
1blood culture has become positive 
In many cases, therefore, effective treatment has to 
be started when fungemia is suspected, which is 
especially difficult in patients without neutropenia 
or any other significant risk factor.
The treatment of fungal infection in general is to 
remove any foreign body present such as central 
venous catheters, IV cannula, and Urethral catheter 
and start administration of antifungal agents, which 
6
should be continued for several weeks at least . We 
present a case of a 17 year old girl who presented 
with Pyrexia of unknown Origin in the haematology 
clinic and was diagnosed with candidaemia.
CASE REPORT
We present ST a 17yr old secondary student who 
presented with 18day history of fever, generalized 
body weakness and abdominal pain. A clinical 
diagnosis of sepsis with anaemia was made and 
patient was commenced on empirical antibiotics, 
patient was given antimalarials (e mal and 
camoquine) with no response. She also had IV 
ceftriaxone 1g 12hrly for 5days from the referral 
hospital, on admission she was started on IV 
Augmentin 600mg 8hrly which was subsequently 
changed to IV ciprofloxacin and metronidazole. 
Patient had this for 5days and still continued to have 
0
spikes of temperature with Tmax of 40.1  C. Five 
days into the admission patient's temperature 
continued to spike despite antibiotics.  Full blood 
.
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Count revealed Pancytopenia with associated 
19
persistent anaemia and WBC =1.2X 10 . Patient 
continued to be anemic despite repeated blood 
transfusions (x7). Blood film for malaria Parasite 
done was negative. Abdominopelvic USS revealed 
hepatosplenomegaly with retroperitoneal 
lymphadenopathy. CXR: was normal, ESR= 
133mm/hr. Efforts made to do bone marrow 
aspiration were not successful as the features of 
sepsis continued and her PCV continued to drop in 
spite of the multiple blood transfusions. 
Blood Culture yielded heavy growth of Candida 
albicans. When the result of blood culture was 
available patient was started on IV Fluconazole 
10mg/kg/day, steroid therapy was also commenced 
and bone marrow aspiration was strongly 
considered because of elusive diagnosis and 
fluctuating clinical condition. However, she was in 
relatively stable condition until early hour of the 
morning 18days post admission when she became 
dyspneic and effort to resuscitate her proved 
abortive and she was certified  dead.
DISCUSSION
In the last 3 decades, there have been significant 
changes in the incidence and epidemiology of 
invasive fungal infections (IFIs). As the life 
expectancy increases and diet becomes more 
westernized more patients are coming down with 
various malignancies including hematological. 
Some of these patients may have to undergo either 
a solid organ or a bone marrow/stem cell transplant 
and In the course of treatment receive potent 
immunosuppressant's for the control of diseases 
thus they are increasingly susceptible to IFIs. As 
these patient populations did not exist 30 years ago, 
our experience in diagnosing these infections is 
11limited primarily to the last couple of decades.
The patient in this case report was managed in the 
haematology unit as a case of a haematological 
autoimmune disorder this is in keeping with the 
12
population of patients who come down with IFI.
Though the diagnosis could not be established fully 
before the patient passed on.
IFI infections have the same presentation as the 
patient, every feature of sepsis as reported above is 
in keeping with reports from other studies. Also 
there was a delay in commencement of antifungal 
as the patient was not commenced on antifungal till 
receipt of a blood culture report.
Candidaemia as a cause of mortality in this case is 
in keeping with reports from studies which show 
that delay in commencement of antifungal 
13
increases mortality in the patients . This also 
brings to fore the need for empirical antifungal to be 
initiated promptly as reported in various studies 
since delay in commencing antifungal increases 
13mortality by 50%.
Diagnostic challenges in isolating the fungi is in 
keeping with studies which show that only 50% of 
blood cultures yield agents of candidaemia, so 
there may be a need for more antigen based  
diagnostic tests such as the mannan antigen and the 
14anti mannan antibodies.
Susceptibility testing to antifungal agents is still not 
the routine in most parts of sub-Saharan Africa as 
various studies have shown that various species of 
the organism have different susceptibilities, and 
some studies have reported increasing resistance to 
15
fluconazole.
In conclusion empirical antifungal should be 
included in the treatment regimens of immune 
compromised patients being managed for sepsis as 
the rate of isolation from the available diagnostics 
is limited and mortality increases with delay in 
commencing antifungal, as a way around this more 
attention should be paid to the use of the mannan 
antigen as it provides fast and reliable results. 
REFERENCES
1. Asmunds Dottir L.R, Erlends Dottir H, Gott 
Fredsson M. Increasing incidence of 
Candidemia: Results from a 20  Year 
Nationwide study in Iceland. J Clin 
Microbiol 2002;40: 3489-92.
2.  Wise G.J, Silver D.A. Fungal Infections of 
the Genitourinary System. J Urol 1993; 
149:1377-88.
3. Fridkin S.K, Jarvis W.R. Epidemiology of 
Nososcomial Fungal Infections. Clin 
Microbiol Rev 1996;9:499-511.
4. Wey S.B, Mori M, Pfaller M.A, et al. 
Hospital-Acquired Candidemia. The 
Attributable Mortality and Excess Length of 
Stay. Archives of Internal Medicine 1998; 
48:2642-5.
5. Fraser V.J, Jones M, Dunkel J, et al. 
Candidemia in Tertiary care Hospital: 
Epidemiology Risk Factors and Predictors 
of mortality. Clin Infect Dis 1992; 
15:414-21.
Candidaemia in the Immunocompromised: A Case for Early Diagnosis/ Detection and Treatment.
Jos Journal of Medicine, Volume 7 No. 2 39
6 . Girmenia C, Martiwo P. Fluconazole and the 
Changing Epidemiology of candidemia. 
Clin  Infect Dis 1998;27:232-4.
7. Colombo A.L, Nucci M, Salomão R, et al. 
High Rate of Non-Albicans Candidemia in 
Brazilian Tertiary Care Hospitals. 
Diagnostic Microbiology and Infectious 
Diseases 1999; 34:281
8. David R. Snydman: Shifting patterns in the 
epidemiology of nosocomial Candida 
infections. Chest journal, may 2003, vol 123 
no.5supp 5005-5035
9. Abi-Said, Anaissiee, Uzon o, Rraad I. The 
e p i d e m i o l o g y  o f  h a e m a t o g e n o u s  
candidiasis caused by different candida spp. 
Clinical Infectious disease1997; 24: 1122-8
10. Koneman,  allen, Janda Winn textbook of 
diagnostic Microbiology, 5th edition. 
Nosocomial candidiasis Emerging species 
reservoir and modes of transmission. 
Clin.Infect dis 1996; 22:89-94.
11. Adam, O. Treatment with piperacillin-
tazobactam and falsepositive Aspergillus 
galactomannan antigen test results for 
patients with hematological malignancies. 
Clin. Infect. Dis. 2004; 38:917-920.
12. Vigoroux S, Morin O, Moreux P, et al. 
C a n d i d a e m i a  i n  P a t i e n t s  w i t h  
haematological malignancy: analysis of 7yr 
e x p e r i e n c e  i n  a  s i n g l e  c e n t e r .  
Haematologica/ The  haematology journal 
2006:91(5):717-719.
13. Asmunds Dottir L.R., Erlends Dottir H., Gott 
Fredsson M. Increasing incidence of 
Candidemia: Results from a 20  Year 
Nationwide study in Iceland. J Clin 
Microbiol.2002; 40:3489-92
14. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of 
i n v a s i v e  a s p e r g i l l o s i s  u s i n g  a  
galactomannanassay: a meta-analysis. Clin 
Infect Dis 2006;42:141727.
15. Coleman DC, Sullivan DJ, Bennett DE, 
Morgan GP, Barry HJ, Shanley DB. 
Candidiasis: The emergence of a novel 
species, Candida dubliniensis. AIDS 
1997;11:557-67.
Candidaemia in the Immunocompromised: A Case for Early Diagnosis/ Detection and Treatment.
Jos Journal of Medicine, Volume 7 No. 2 40
